Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Other Non-Current Liabilities for 14 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 42.06% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 42.06% YoY), while the FY2025 annual figure was $44.0 million, down 94.63% from the prior year.
• Other Non-Current Liabilities climbed to $1.1 billion in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.1 billion in Q1 2026 and bottomed at $3.8 million in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $387.9 million across 5 years, with a median of $44.0 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 98.9% — and 2023, when it surged 21529.53%.
• Ultragenyx Pharmaceutical's Other Non-Current Liabilities stood at $4.8 million in 2022, then surged by 17790.56% to $862.3 million in 2023, then fell by 4.91% to $820.0 million in 2024, then plunged by 94.63% to $44.0 million in 2025, then jumped by 2463.64% to $1.1 billion in 2026.
• Business Quant data shows RARE's Other Non-Current Liabilities at $1.1 billion in Q1 2026, $44.0 million in Q4 2025, and $18.8 million in Q3 2025.